StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)

Close on Nov 17, 2026Market cap $773.79MP/E –Yield –

Monte Rosa Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Monte Rosa Therapeutics's price to sales ratio was 30.6× on Nov 11, 2026, against 5.5× a year earlier. Over the last 3 years it ranged from 1.6× to 213.3×, with a median of 27.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202630.6×+25.3
2025Dec 31, 20255.3×−23.1
2024Dec 31, 202428.4×–

More Monte Rosa Therapeutics figures

See a number that looks wrong?